Phaseline

Companies › Genfit

Genfit: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GNS561
MEK inhibitor
MAP2K1Phase 1CholangiocarcinomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05874414GNS561Phase 1CholangiocarcinomaOncologyDec 2027

Targets

MAP2K1 (1)

Companies with the same targets

Roche AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma Pasithea Therapeutics Novartis Merck KGaA SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Nested Therapeutics Verastem

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.